NASDAQ:ACOR - Acorda Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$28.70 -0.90 (-3.04 %)
(As of 07/19/2018 05:36 AM ET)
Previous Close$29.60
Today's Range$28.50 - $29.60
52-Week Range$16.55 - $36.35
Volume307,800 shs
Average Volume479,242 shs
Market Capitalization$1.39 billion
P/E RatioN/A
Dividend YieldN/A
Acorda Therapeutics logoAcorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Receive ACOR News and Ratings via Email

Sign-up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic


Debt-to-Equity Ratio0.61
Current Ratio3.65
Quick Ratio3.41


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$588.29 million
Price / Sales2.30
Cash Flow$1.7268 per share
Price / Cash16.62
Book Value$11.12 per share
Price / Book2.58


EPS (Most Recent Fiscal Year)$1.04
Net Income$-223,350,000.00
Net Margins-36.98%
Return on Equity-3.38%
Return on Assets-1.63%


Outstanding Shares47,070,000
Market Cap$1,393.17

The Truth About Cryptocurrencies

Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics Inc (NASDAQ:ACOR) announced its quarterly earnings data on Wednesday, May, 2nd. The biopharmaceutical company reported $0.14 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.33 by $0.19. The biopharmaceutical company earned $106.17 million during the quarter, compared to analysts' expectations of $130.94 million. Acorda Therapeutics had a negative return on equity of 3.38% and a negative net margin of 36.98%. Acorda Therapeutics's revenue for the quarter was down 11.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.08) EPS. View Acorda Therapeutics' Earnings History.

When is Acorda Therapeutics' next earnings date?

Acorda Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Acorda Therapeutics.

What price target have analysts set for ACOR?

13 analysts have issued 12 month price objectives for Acorda Therapeutics' stock. Their forecasts range from $13.00 to $37.00. On average, they anticipate Acorda Therapeutics' stock price to reach $21.8333 in the next year. This suggests that the stock has a possible downside of 23.9%. View Analyst Ratings for Acorda Therapeutics.

What is the consensus analysts' recommendation for Acorda Therapeutics?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last year. There are currently 1 sell rating, 9 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

What are Wall Street analysts saying about Acorda Therapeutics stock?

Here are some recent quotes from research analysts about Acorda Therapeutics stock:
  • 1. According to Zacks Investment Research, "Acorda is presently working on strengthening its Parkinson’s pipeline by focusing on the late stage candidate Inbrija in its portfolio. Inbrija’s NDA is under review in the United States and EU. Acorda boasts a strong pipeline addressing a wide range of disorders. The restructing initiative is also encuraging. The company’s share price has outperformed the industry so far this year. However, the company’s key multiple sclerosis drug Ampyra is expected to face generic competition from mid-2018 in the United States. Hence, Acorda’s dependence on Ampyra to draw major part of its revenues is concerning. Moreover, Inbrija received a refusal-to-file letter from the FDA for NDA for Inbrija last August. This in turn delayed its expected commercial launch, which was anticipated much earlier." (7/3/2018)
  • 2. HC Wainwright analysts commented, "Ziopharm’s CAR-T Programs Make a Splash at ASH; Reiterate Buy Ziopharm’s 2nd-gen CAR-T shows promise in early study. We attended the 2017 Annual Meeting of the American Society of Hematology (ASH) over the last weekend, where Ziopharm presented interim results from the ongoing Phase 1 clinical study in patients with CD19 + leukemia or lymphoma treated with Ziopharm’s second generation CD19 + CAR-T therapy. Recall, Ziopharm’s second generation CAR-T cells were manufactured using the company’s proprietary Sleeping Beauty (SB) transposon platform which shortens the manufacturing process to two weeks compared to the typical 3-4 weeks for currently approved CAR-T therapies, such as Kymriah from Novartis (NVS; not rated) and Yescarta from Gilead (GILD; not rated). The results from the Phase 1 study show that treatment of patients with relapsed/refractory leukemia or lymphoma (n = 8) resulted in a 50% complete response rate after one month of therapy." (12/14/2017)
  • 3. Cantor Fitzgerald analysts commented, "Not what ACOR stock needed. ACOR announced this morning that an increase in blood monitoring for agranulocytosis is being implemented for subjects in the Phase 3 trial of tozadenant in Parkinson’s disease (PD)." (11/15/2017)

Who are some of Acorda Therapeutics' key competitors?

Who are Acorda Therapeutics' key executives?

Acorda Therapeutics' management team includes the folowing people:
  • Dr. Ron Cohen, Founder, CEO, Pres & Director (Age 62)
  • Mr. David Lawrence, Chief of Bus. Operations & Principal Accounting Officer (Age 60)
  • Ms. Lauren M. Sabella, Chief Commercial Officer (Age 57)
  • Mr. Andrew Asa Hindman, Chief Bus. Officer (Age 45)
  • Dr. Burkhard Blank, Chief Medical Officer (Age 63)

Has Acorda Therapeutics been receiving favorable news coverage?

News coverage about ACOR stock has been trending somewhat positive this week, Accern reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Acorda Therapeutics earned a news sentiment score of 0.09 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.95 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Acorda Therapeutics' major shareholders?

Acorda Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Xact Kapitalforvaltning AB (0.02%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Barry E Greene, Burkhard Blank, David Lawrence, Ian F Smith, Jane Wasman, Lauren M Sabella, Lorin Randall, Richard P Batycky, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View Institutional Ownership Trends for Acorda Therapeutics.

Which institutional investors are buying Acorda Therapeutics stock?

ACOR stock was bought by a variety of institutional investors in the last quarter, including Xact Kapitalforvaltning AB. Company insiders that have bought Acorda Therapeutics stock in the last two years include Ron Cohen and Scopia Capital Management Lp. View Insider Buying and Selling for Acorda Therapeutics.

How do I buy shares of Acorda Therapeutics?

Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acorda Therapeutics' stock price today?

One share of ACOR stock can currently be purchased for approximately $28.70.

How big of a company is Acorda Therapeutics?

Acorda Therapeutics has a market capitalization of $1.41 billion and generates $588.29 million in revenue each year. The biopharmaceutical company earns $-223,350,000.00 in net income (profit) each year or $1.04 on an earnings per share basis. Acorda Therapeutics employs 484 workers across the globe.

How can I contact Acorda Therapeutics?

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.

MarketBeat Community Rating for Acorda Therapeutics (NASDAQ ACOR)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  294 (Vote Outperform)
Underperform Votes:  384 (Vote Underperform)
Total Votes:  678
MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe ACOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/19/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.